Q-omics provides the consensus-scored CAPN13 profile across patient tissues and cancer cell-line models. CAPN13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, CAPN13 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CAPN13 RNA expression shows 18,488 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight READ, KIRC, and GBM as cancer lineages where CAPN13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN13 survival associations across molecular data types. CAPN13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN13 RNA expression–survival associations across cancer types. High CAPN13 expression shows unfavorable associations in UVM, DLBC and KIRP, but favorable associations in READ, KIRC and OV. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for CAPN13 RNA expression.
This table summarizes CAPN13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN13 shows lower tumor expression in KIRC, COAD, KIRP and LUSC and higher tumor expression in BRCA and UCEC. The KIRC box plot shows higher CAPN13 RNA expression in normal versus tumor tissue (log2 FC = −1.418, t-test p < 0.001).
This table shows molecular features associated with CAPN13 in patient tissues and cancer cell lines. In patient samples, CAPN13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
